Driving access to Innovative Therapies Through Strategic Partnerships Innovation is only meaningful when it reaches the people who need it. At PharmaBlue, we help biotech and pharmaceutical companies bring 30+ innovative therapies and orphan drugs to French patients—faster and more…
Rare diseases: At the core of our mission At PharmaBlue, we’ve spent the past decade supporting biotech innovators in bringing their rare disease therapies to patients in France—quickly, compliantly, and with care. As a licensed Exploitant, we specialize in managing…
Thanks to early access programs, drugs are on average available in France 200 days before their first regulatory approval (FDA or EMA). In this context, early access programs can be extremely attractive for pharmaceutical companies developing life - transforming therapies.…
Download our latest Case Study: Exploitant services for MAA product You will learn more about: ▪ Exploitant status in France ▪ Exploitant services ▪ Pharmablue our Exploitant establishement
Expanded Access is a treatment option that allows the use of an unauthorized medicine (investigational drugs). Under strict conditions, products in development (with ongoing clinical trial) can be made available to groups of eligible patients who have a disease with…